Arvinas Inc

ARVN

Healthcare|Biotechnology|USA

$8.28

-0.27 (-3.10%)

Tangible Book

$6.00

About

Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.

Stock Price

+4.9%(1Y)

Pipeline Summary

26 total trials

Phase 1

Phase 2

Phase 3

Phase 4

Recruiting: 2Completed: 16Active: 8

Active Trials (10)

A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.

NCT06393738Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL)

Phase 1Recruiting

Enrollment: 255 participants

A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer.

NCT06206837Breast Cancer

Phase 1Phase 2Active

Enrollment: 71 participants

A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation

NCT07023731KRAS G12D Mutation

Phase 1Phase 2Active

Enrollment: 159 participants

TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A)

NCT05548127Breast Cancer

Phase 1Phase 2Active

Enrollment: 37 participants

A Study to Learn How the Body Processes the Study Medicine Called Vepdegestrant in People With Loss of Liver Function

NCT07231991Healthy Participants

Phase 1Recruiting

Enrollment: 24 participants

View all 10 active trials →

BioScore

4.3/10

Cautious

Ownership

Recent Insider Trades

Saik AndrewSELL

2026-06-245,696 shares @ $8.16

Cacace Angela MSELL

2026-06-172,576 shares @ $7.6

Teel RandySELL

2026-05-212,209 shares @ $9.04

Berkowitz NoahSELL

2026-05-1111,108 shares @ $9.94

Teel RandySELL

2026-05-119,657 shares @ $9.94

Recent News

2026-06-24 17:00:08

Data last updated: Jul 13, 2026, 10:40 AM